Bibliography - Professor Tim Hughes

H-FACTOR = 86, Citations 47935

  1. Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, leCoutre P, Ottmann O, Heinrich MC. Steehmann JL, Deininger MW, Janssen JJ, Mahon FX, Minami Y, Yeung DT, Ross DM, Tallman MS, Park JH, Druker BJ, Hynds D, Duan Y, Meille C, Hourcade-Potelleret F, Vanasse G, Lang F, Kim DW. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. New England Journal of Medicine 19-02328.R3 Sept 2019. Accepted for publication.
  2. Shanmuganathan N, Braley JA. Yong ASM, Hiwase DK, Yeung DT, Ross DM, Hughes TP, Branford S. Modeling the safe minimum frequeny of molecular monitoring for CML patients attempting treatment free remission. Blood July 2019 134(1) 85-89 CIT 2
  3. Branford S, Kim DDH, Apperley JF, Eid Ca, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambarcort-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, Radich JP, Hochhaus A, Hughes TP. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia 17 June 2019 DOI: 10.1038/s41375-019-512-y
  4. Kok CH, Yeung DT, Liu L, Watkins DB, Leclercq TM, Dang P, Saunders VA, Reynolds J, White DL, Hughes TP. Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. Blood Advances May 2019. 3(10) 1610-1621
  5. Ross DM, Pagani IS, Irani YD, Clarson, J, LeclercqT, Dang P, McLean J, Saunders VA, Carne L, Reynolds J, Ritchie DS, White DL, Branford S, Hughes TP, Yong A. Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in CML. British Journal of Haematology. Aug 2019 186(3) 56-60
  6. Chhetri R, Wee LYA, Sinha R, Kutyna MM, Pham A, Stathopoulos H, Nath L, Nath SV, Wickham N, Hughes TP, Singhal D, Roxby DJ, Hiwase DK. Red cell autoimmunization and alloimmunization in myelodysplastic syndromes: prevalence, characteristic and significance. Haematologica Feb 2019
  7. Hughes TP, Laneuville P, Rousselot P, Snyder DS, Rea D, Shah NP, Paar D, Abruzzese E, Hochhaus A, Lipton JH, Cortes JE. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica Jan 2019. 104(1) 93-101 CIT 3
  8. Shanmuganathan N, Branford S, Hughes TP, Hiwase D. Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI. Blood Advances Dec 2018 Vol 3 (3) 370-374 CIT 2
  9. Ross DM, Pagani IS, Shanmuganathan N, Kok CH, Seymour JF, Mills AK, Filshie RJ, Arthur CK, Dang P, Saunders VA, Braley J, Yong AS, Yeung DT, White DL, Grigg AP, Schwarer AP, Branford S, Hughes TP. Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia Dec 2018. 32(12) 2572 CIT 3
  10. Pagani IS, Dang P, O Kommers IO, Goyne JM, Nicola M, Saunders VA, Braley J, White DL, Yeung DT, Branford S, Hughes TP, Ross DM. BCR-ABL 1 geonomic DNA PCR response kinetics during first-line imatinib treatment of chonic myeloid leukaemia. Haematologica Dec 2018. 103(12) 2026-2032 CIT 8
  11. Shanmuganathan N, Hughes TP. Molecular monitoring in CML: how deep? How often? How should it influence therapy? Blood Nov 2018. 132(20) 2125-2133 CIT 8
  12. Tvorogov D, Thomas D, Liau NPD, Dottore M, Dottore M, Barry EF, Lathi M, Kan WL, Hercus TR, Stomski F, Hughes TP, Tergaonkar V, Parker MW, Ross DM, Majeti R, Babon JJ, Lopez AF. Accumulation of JAK activation loop phosphorylation is linked to type 1 JAK inhibitor withdrawal syndrome in myelofibrosis. Science Advances Nov 2018. 4(21) eaat3834 CIT 1
  13. Lu L, Kok CH, Saunders VA, Wang J, McLean JA, Hughes TP, White DL. Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines. Oncotarget Oct 2018 9(78) 34735-34747 CIT 1
  14. Branford S, Wang P, Yeung DT, Thomson D, Purins A, Wadham C, Shahrin NH, Marum JE, Nataren N, Parker WT, Georghegan J, Feng J, Shanmuganathan N, Mueller MC, Dietz C, Stangl D, Donaldson Z, Altamura H, Georgievski J, Braley J, Brown A, Hahn C, Walker I, Kim SH, Choi SY, Park SH, Kim DW, White DL, Yong A, Ross DM, Scott HS, Schreiber AW, Hughes TP. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood Aug 2018. 132(9) 948-961 CIT 14
  15. Hercus TR, Kan WLT, Broughton SE, Tvorogov D, Ramshaw HS, Sandow JJ, Nero TL, Dhagat U, Thompson EJ, Karen S Cheung KS, Shing T, McKenzie DR, Wilson NJ, Owczarek CM, Vairo G, Nash AD, Tergaonkar V, Hughes TP, Ekert PG, Samuel MS, Bonder CS, Grimbaldeston MA, Parker MW, Lopez AF. Role of the β Common (βc) Family of Cytokines in Health and Disease. Cold Spring Harbor perspectives in biology. June 2018 10(6) a028514 CIT 4
  16. Ross DM, Burbury KL, Grigg AP, Hughes TP, Seymour JF. Management of Pregnancy in Women with Chronic Myeloid Leukemia. Journal of Clinical Oncology. JCO2018786137 Sept 2018 36(25) 2657-2658 CIT 1
  17. Nair SS, Luu PL, Qu W, Maddugoda M, Huschtscha L, Reddel R, Chenevix-Trench G, Toso M, Kench JG, Horvath LG, Hayes VM, Stricker PD, Hughes TP, White DL, Rasko JE, Wong JJL, Clark SJ. Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten. Epigenetics & Chromatin. May 2018 11(1) 24 CIT 4
  18. McClure BJ, Heatley SL, Kok CH, Sadras T, An J, Hughes TP, Lock RB, Yeung DT, Sutton R, White DL. Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression. British Journal of Cancer April 2018 118 (7) 1000 CIT 2
  19. Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, Ailawadhi S, Lipton JH, Turkina AG, Paz R, Moiraghi B, Nicolini FE, Dengler J, Sacha T, Takahashi N, Fellague-Chebra R, Acharya S, Wong S, Jin Y, Hughes TP. Treatment-Free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, Phase 2, open-label study. Annals of Internal Medicine April 2018 CIT 35
  20. Hiwase D, Tan P, D’Rozario J, Taper J, Powell A, Irving I, Wright M, Branford S, Yeung DT, Anderson L, Gervasio O, Levetan C, Roberts W, Solterbeck A, Traficante R, Hughes TP. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are tolerant to prior tyrosine kinase inhibitors. Leukaemia Research April 2018 (67) 109-115 CIT 1
  21. Eadie LN, Hughes TP, White DL. Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy. Leukemia Oct 2018 32(1) 2288 CIT 3
  22. Eadie LN, Saunders VA, Branford S, White DL, Hughes TP. The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro. Oncotarget March 2018 9(17) 13423 CIT 5
  23. Cortes JE, Kim DW, Pinilla-Ibarz J, Le Courte PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia:final 5-year results of the phase 2 PACE trial. Blood Jan 2018 Vol 132 (4) 393-404 CIT 62
  24. Eadie L, Dang P, Goyne JM, Hughes TP, White DL. ABCC6 plays a significant role in the transport of nilotinib and dasatanib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells. PLOS One Jan 2018 13(1) CIT 2
  25. Broughton SE, Hercus TR, Nero TL, Kan WL, Barry EF, Dottore M, Cheung KS, Shing T, Morton CJ, Dhagat U, Hardy MP, Wilson NJ, Downton MT, Schieber C, Hughes TP, Lopez AF, Parker MW. A dual role for the N-terminal domain of the IL-3 receptor in cell signalling. Nature Communications Jan 2018. 9(1) 386 CIT 7
  26. Heatley SL, Sadras T, Kok CH, Nievergall E, Quek K, Dang P, McClure B, Venn N, Moore S, Suttle J, Law T, Ng A, Muskovic W, Norris MD, Revesz T, Osborn M, Moore AS, Suppiah R, Fraser C, Alvaro F, Hughes TP, Mullighan CG, Marshall GM, Pozza LD, Yeung DT, Sutton R, White DL. High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Haematologica Dec 2017 102 (12) e490-e493 CIT 11
  27. Sadras T, Heatley SL, Kok CH, Dang P, Galbraith KM, McClure BJ, Muskovic W, Venn NC, Moore S, Osborn M, Revesz T, Moore AS, Hughes TP, Yeung D, Sutton R, White DL. Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2- rearrangedacute lymphoblastic leukemia patients with distinct secondary lesions. Cancer Letters Nov 2017 408 92-101 CIT 7
  28. Rasko JE, Hughes TP. First approved Kinase Inhibitor for AML. Cell Nov 2017. 171(5) 981. CIT 8
  29. Sadras T, Heatley SL, Kok CH, McClure BJ, Yeung D, Hughes TP, Sutton R, Ziegler DS, White DL. A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH. Cancer Genetics Oct 2017 (216) 86-90 CIT 2
  30. Pagani I, Kok CH, Saunders VA, Van der Hoek MB, Heatley SL, Schwarer AP, Hahn CN, Hughes TP, White DL, Ross DM. A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia. The Journal of Molecular Diagnostics. Sept 2017 19 (5) 711-721 CIT 4
  31. Marum JE, Yeung DT, Purins L, Reynolds J, Parker WT, Stangle D, Wang PPS, Price DJ, Tuke J, Schreiber AW, Scott HS, Hughes TP, Branford S. ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure. Blood Advances Aug 2017 1 (18) 1369-1381 CIT 4
  32. Hughes TP, Leber B, Cervantes F. Spector N. Pasquini R, Celmentino NCD, Schwarer AP, Dorlhiac-Llacer PE, Mahon FX, Rea D, Guerci-Bresler A, Kamel-Reid S, Bendit I, Acharya S, Glynos T, Dala D, Branford S, Lipton JH. Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results. Leukemia Aug 2017 31(11) 2529. CIT 9
  33. Barratt DT, Cox HK, Menelaou A, Yeung DT, White DL, Hughes TP, Somogyi A. CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients. Clinical Pharmacokinetics Aug 2017 56(8) 977-985 CIT 8
  34. Hughes TP, Munhoz E, Salvino MA, Ong TC, Elhaddad A, Shortt J, Quash H, Pavlovsky C, Louw VJ, Shih LY, Turkina AG, Meillon L, Jin Y, Acharya S, Dala D, Lipton JH. Nilotinib dose‐optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd. British Journal of Haematology. Oct 2017 179(2) 219-228 CIT 7
  35. Pagani IS, Dang P, Kommers IO, Goyne J, Saunders VA, Prime JA, White DL, Branford S, Hughes TP, Ross DM. Comparison of Genomic DNA and reverse transcriptase Q-PCR for the monitoring of first-line imatinib treatment: an ALLG CML9 sub-study. June 2017 Haematologica 102 181-182
  36. Hughes TP, Saglio G. Expert opinion on the treatment of Refractory Chronic Phase CML. European Oncology & Haematology. June 2017 13(1) 17-23 CIT 1
  37. Cortes JE, Kantarjian HM, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, Baccarani M, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Lustgarten S, Santillana S, Rivera VM, Clackson T, Mueller MC. 5-year results from the pivoltal phase 2 ponatinib pace trial: efficacy, safety and landmark analysis in heavily pretreated patients (PTS) with chronic-phase chronic myeloid leukemia (CP-CML). Haematologica June 2017 102 236-237 CIT 1
  38. Hughes A, Clarson J, Gargett T, Yu W, Brown MP, Lopez AF, Hughes TP, Yong A. Comment on “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study”. Leukemia Research April 2017 55 55-57 CIT 1
  39. Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes TP, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ, Kantarjian HM, Cortes JE. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphiachromosome-positive leukemias with the T315I mutation. Cancer Aug 2017 123 (15) 2875-2880 CIT 28
  40. Wang J, Lu L, Kok C, Saunders VA, Goyne J, Dang P, Leclercq T, Hughes TP, White DL. Increased peroxisome proliferator-activated receptor-gamma activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells. Haematologica May 2017 102 (5) 843-853 CIT 1
  41. Hochhaus A, Larson RA, Guilhot F, Radich J, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann C, Menssen H, Kantarjian H, O’Brien S, Druker B. IRIS Final Analysis: Long-Term outcomes with Imatinib treatment for CML. New England Journal Medicine. March 2017 376 (1) 917-927 CIT 307
  42. Hughes A, Clarson J, Tang C, Vidovic L, White DL, Hughes TP, Yong ASM. CML patients with deep molecular responses to TKI have restored immune effectors, decreased PD-1 and immune suppressors. Blood 2 Mar 2017 129/9 1166-1176 CIT 60
  43. Eadie LN, Hughes TP, White DL. Response to ‘Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics? Leukemia. Mar 2017 31(3) 769 - 770
  44. Hughes TP, Ross D. Targeted therapies: Remembrance of things past: discontinuation of second-line TKI treatment in CML. Nature Reviews Clinical Oncology. Nature Reviews Clinical Oncology. Jan 2017 14(4) 201-202 CIT 2
  45. Banjar H, Ranasinghe D, Brown F, Adelson D, Kroger T, Leclercq T, White DL, Hughes TP, Chaudhri N. Modelling predictors of Molecular response to frontline Imatinib for patients with Chronic Myeloid Leukaemia. PLOS One Jan 2017 12(1) e0168947 CIT 3
  46. Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, Marzinzik A, Pelle X, Donovan J, Zhu W, Buonamici S, Hassan Q, Lombardo F, Iyer V, Palmer M, Berellini G, Dodd S, Thohan S, Bitter H, Branford S, Ross D, Hughes TP, Petruzzelli L, Vanasse KG, Warmuth M, Hofmann F, Keen N, Sellers WR. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL. Nature. 30 March 2017 543 (7647) 733-737 CIT 108
  47. Eadie LN, Dang P, Saunders VA, Yeung DT, Osborn MP, Grigg AP, Hughes TP, White DL. The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. Leukemia July 2016 1 8 CIT 34
  48. Sopper S, Mustjoki S, White DL, Hughes TP, Valent P, Burchert A, Gjertsen BT, Gastl G, Baldauf M, Trajanoski Z, Giles F, Hochhaus A, Ernst T, Schenk T, Janssen JWM , Ossenkoppele GJ, Porkka K, Wolf D. Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to Tyrosine Kinase Inhibitor (TKI) therapy in early Chronic Phase Chronic Myelogenous Leukemia (CML-CP). Journal of Clinical Oncology Nov 2016 35(2) 175-184 CIT 13
  49. Eadie LN, Hughes TP, White DL. ABCB1 overexpression is a key initiator of Resistance to Tyrosine Kinase inhibitors in CML cell lines. PLOS ONE 11(8) e0161470 August 2016 CIT 21
  50. le Coutre PD, Hughes TP, Mahon FX, Kim DW, Steegmann JL, Shah NP, Gooden K, Wallis N, Cortes JE. Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials. Leukemia July 2016 (30) 1593-1596 CIT 9
  51. Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, Clackson T, Haluska FG, Baccarani M, Cortes JE, Guilhot F, Hochhaus A, Hughes TP, Kantarjian HM, Shah NP, Talpaz M, Deininger MW, EPIC investigators. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. The Lancet Oncology May 2016 17(5) 612-621 CIT 108
  52. Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, Gambacorti-Passerini C, Saglio G, Cortes J, Daley GQ. Chronic myeloid leukemia: reminiscences and dreams. Haematologica May 2016 101(5) 541-558 CIT 41
  53. Latham S, Bartley PA, Budgen B, Ross DM, E, Hughes E, Branford S, White DL, Hughes TP, Morley A. BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukemia. Journal of Clinical Pathology 203538 Feb 2016 CIT 4
  54. Nievergall E, Reynolds J, Kok C, Watkins D, Biondo M, Busfield SJ, Vairo G, Yeung DT, Lopez AF, Hiwase DK, Hughes TP, White DL. TGF- α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia June 2016 30(6) 1263-1273 CIT 19
  55. Kok CH, Watkins D, Wang J, Saunders V, Goyne J, Pagani I, Dang P, McLean J, Yeung D, Hughes TP, White D. High Gene expression of HIST1H2AG and HIST1H4A reduces imatinib uptake into CML cells and predicts poor reponse to frontline imatinib therapy. Haematologica June 2016 101 152-153
  56. Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DQ, Issaragrisil S, le Coutre P, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantajian HM. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid Leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 30(5) 1044-1054 May 2016 CIT 316
  57. Deininger M, Hodgson GJ, Shah N P, Cortes JE, Kim DW, Nicolini FE, Talpaz M, Baccarani M, Mueller MC, Li J, Parker WT, Lustgarten S, Clackson T, Haluska FG, Guilhot F, Kantarjian HM, Soverini S, Hochhaus A, Hughes TP, Rivera VM, Branford S. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood Feb 2016 127 (6) 703-712 CIT 54
  58. Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. BLOOD 2016 128 (1) 17-23 CIT 172
  59. Parker WT, Yeung DT, Yeoman AL, Altamura HK, Jamison B, Field CR, Hodgson JG, Lustgarten S, Rivera VM, Hughes TP, Branford S. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. BLOOD April 2016 Vol 127 1870 -1880 CIT 36
  60. Yeung DT, Tang C, Vidovic L, White DL, Branford S, Hughes TP, Yong A. KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy. BLOOD 2015 Dec 126 (25) 2720-2723 CIT 13
  61. Watkins DB, Hughes TP, White DL. OCT1 and imatinib transport in CML: is it clinically relevant? Leukemia. 2015 29;10 1960-1969. CIT 24
  62. Mueller MC, Baccarani M, Deininger MW, Guilhot F, Hochhaus A, Hughes TP, Shah NP, Talpaz M, Lustgarten S, Rivera VM, Clackson T. Haluska FG, Cortes JE. Oncology Research and Treatment Oct 2015 38 179-180
  63. White DL, Hughes TP. Living with CML: is death no longer the end (point)? BLOOD July 2015 126(1) 2-4 CIT 1
  64. Ong J, Yeung DT, Filshie R, Hughes TP, Nandurkar H. Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia. International Journal of Hematology 2015 Vol 1, 1-4 CIT 5
  65. Cortes J, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Lustgarten S, Rivera VM, Tim Clackson T, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Shah NP, Kantarjian HM. Ponatinib efficacy and safety in heavily pretreated leukemia patients: 3-year results of the PACE trial. Haematolgica June 2015 100(P234) 61 CIT 16
  66. Pritchard J, Lustgarten S, Hodgson JG, Baccarani M. Cortes JE, Deninger MW, Guilhot F, Hughes TP, Shah NP, Talpaz M. Mueller MC. Clackson T, Haluska FG, Knickerbocker R, Rivera VM. Haematologica June 2015. 100 448-449 CIT 1
  67. Lickliter JD, Taylor K, Szer J, Grigg A, Arthur C, Hughes TP, Durrant S, Filshie R, Irving I, Seldon M, Ellacott J, Boyd AW, D'Rozario j, Rooney K, Lynch K, Bradstock K. An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial. Mar 2015 Leukemia & Lymphoma 56:3 630-638 CIT 3
  68. Hughes TP, Saglio G, Quintas-Cardama A, Mauro MJ, Kim DW, Lipton JH, Bradley B, Ukropec J, Hochhaus A. BCR-ABL1 mutuation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia Sept 2015 29(9) 1832-1838 CIT 41
  69. Bartley PA, Latham S, Budgen B, Ross DM, Hughes E, Branford S, White DL, Hughes TP, Morley A. A DNA Real-Time Quantitative PCR Method Suitable for Routine Monitoring of Low Levels of Minimal Residual Disease in Chronic Myeloid Leukemia Journal of Molecular Diagnostics Mar 2015 17(2) 185-192 CIT 18
  70. Lu L, Saunders V, Leclercq T, Hughes TP, White D. Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells. Leukemia,13 Feb 2015 1038/leu.2015.35 CIT 14
  71. Baccarani M, Mauro MJ, Cortes JE, Hochhaus A, Hughes TP, Guilhot F, Deininger MW, Kantarjian HM, Shah NP, Bixby D, Flinn IW, Lustgarten S, Rivera VM, Haluska FG, Clackson T, Talpaz M. Long-term Follow-up of Ponatinib Efficacy and Safety in Patients With the T315I Mutation in the Phase 1 and Phase 2 (PACE) Trials. Hematologica 2015 100(1) 65 CIT 2
  72. Yeung D, Osborn MP, White DL, Branford S, Braley J, Herschtal, Kornhauser M, Issa S, Hiwase DK, Hertzberg M, Schwarer A, Filshie R, Arthur C, Kwan YL, Trotman J, Forsyth CJ, Taper J, Ross DM, Beresford J, Tam C, Mills AK, Grigg AP, Hughes TP. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. BLOOD Feb 2015; 125: 915 - 923 CIT 75
  73. Yeung DT, Moulton DJ, Heatley SL, Nievergall E, Dang P, Braley J, Branford S, Moore S, Mulligan CG, Hughes TP, White DL. Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment. Leukemia Jan 2015 29(1) 230-233 CIT 16
  74. Schafranek L, Nievergall E, Powell JA, Hiwase DK, Leclercq T, Hughes TP, White DL. Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia. Leukemia Jan 2015 29(1) 76-85 CIT 32
  75. Yeung DT, Hughes TP. Chronic Myeloid Leulaemia in Postgradue Haematology. Seventh Edition, Wiley Blackwell pp 419-437. DOI:10.1002/9781118853771.ch24 2015
  76. Olshen A, Tang M, Cortes J, MGonen M, Hughes TP, Branford S, Quintas-Cardama A, Michor F. Dynamics of Chronic Myeloid Leukemia response to Dasatinib, Nilotinib, and High-Dose Imatinib. Haemotologica November 2014 99: 1701-1709 CIT 12
  77. Roberts KG, Li Y,Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, Chen SC, Easton J, Cheng J, Boggs K, Santiago-Morales N, Iacobucci I, Fulton RS, Wen J, Valentine M, Cheng C, Paugh SW, Devidas M, Chen IM, Reshmi S, Smith A, Hedlund E, Gupta P, Nagahawatte P, Wu G, Chen X, Yergeau D, Vadodaria B, Mulder H, Winick NJ, Larsen EC, Carroll WL, Heerema NA, Carroll AJ, Grayson G, Tasian SK, Moore AS, Keller F, Frei-Jones M, Whitlock JA, Raetz EA, White DL, Hughes TP, Guidry Auvil JM, Smith MA, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Gastier-Foster JM, Mardis E, Wilson RK, Loh ML, Downing JR, Hunger SP, Willman CL, Zhang J, Mullighan CG. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014 Sep 11;371(11):1005-15. CIT 687
  78. Seymour JF, Kim DW, Rubin E, Haregewoin A, Clark J, Watson P, Hughes TP, Dufva I, Jimenez JL, Mahon FX, Rousselot P, Cortes J, Martinelli G, Papayannidis C, Nagler A, Giles FJ. A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer J. 2014 29(1) 76-85 CIT 38
  79. Parker WT, Phillis SR, Yeung DT, Hughes TP, Scott HS, Branford S. Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination. Blood. 2014 Jul 3;124(1):153-5 CIT 22
  80. Hughes TP, Lipton JH, Spector N, Cervantes F, Pasquini R, Clementino NC, Dorlhiac Llacer PE, Schwarer AP, Mahon FX, Rea D, Branford S, Purkayastha D, Collins L, Szczudlo T, Leber B. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood. 2014 Jul 31;124(5):729-36. CIT 68
  81. Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Donaldson Z, Leong M, Fletcher L, Seymour JF, Grigg AP, Ross DM, Hughes TP. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 2014 Jul 24;124(4):511-8 CIT 140
  82. Ross DM, Hughes TP. How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia. Br J Haematol. 2014 Jul;166(1):3-11 CIT 51
  83. Baccarani M, Druker BJ, Branford S, Kim DW, Pane F, Mongay L, Mone M, Ortmann CE, Kantarjian HM, Radich JP, Hughes TP, Cortes JE, Guilhot F.Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. Int J Hematol. 2014 May;99(5):616-24 CIT 34
  84. Hughes TP, Hochhaus A, Kantarjian HM, Cervantes F, Guilhot F, Niederwieser D, le Coutre PD, Rosti G, Ossenkoppele G, Lobo C, Shibayama H, Fan X, Menssen HD, Kemp C, Larson RA, Saglio G. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica. 2014 Jul;99(7):1204-11 CIT 32
  85. Jabbour EJ, Hughes TP, Cortés JE, Kantarjian HM, Hochhaus A Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leuk Lymphoma. 2014 Jul;55(7):1451-62 CIT 36
  86. Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, Nakaseko C, De Souza CA, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014 Feb 27;123(9):1353-60 CIT 198
  87. Nievergall E, Ramshaw HS, Yong AS, Biondo M, Busfield SJ, Vairo G, Lopez AF, Hughes TP, White DL, Hiwase DK. Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014 Feb 20;123(8):1218-28. CIT 58
  88. Eadie LN, Hughes TP, White DL. Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib. Clin Pharmacol Ther. 2014;95(3):294-306. CIT 48
  89. Kok CH, Leclercq T, Watkins DB, Saunders V, Wang J, Hughes TP, White DL. Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients. Leukemia. 2014;28(3):702-705 CIT 4
  90. Cervantes F, Spector N, Lipton JH, Etienne G, Pasquini R, Clementino NC, Guerci-Bresler A, Forrest D, Schwarer AP, Acharya A, Collins L, Szczudlo T, Hughes TP. Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36 Month Follow up. Blood Nov 2013 122(21) 94-95 CIT 16
  91. Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia. 2013 Apr;27(4): 907-913 CIT 28
  92. White HE, Hedges J, Bendit I, Branford S, Colomer D, Hochhaus A, Hughes TP, Kamel-Reid S, Kim DW, Modur V, Müller MC, Pagnano KB, Pane F, Radich J, Cross NC, Labourier E. Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. Clin Chem. 2013 Jun;59(6): 938-948 CIT 39
  93. Hercus TR, Dhagat U, Kan WL, Broughton SE, Nero TL, Perugini M, Sandow JJ, D'Andrea RJ, Ekert PG, Hughes TP, Parker MW, Lopez AF. Signalling by the βc family of cytokines. Cytokine Growth Factor Rev. 2013 Jun;24(3):189-201 CIT 48
  94. Stein AM, Martinelli G, Hughes TP, Müller MC, Beppu L, Gottardi E, Branford S, Soverini S, Woodman RC, Hochhaus A, Kim DW, Saglio G, Radich JP. Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. BMC Cancer. 2013 Apr 2;13(1):173. CIT 13
  95. Ross DM, O'Hely M, Bartley PA, Dang P, Score J, Goyne JM, Sobrinho-Simoes M, Cross NC, Melo JV, Speed TP, Hughes TP, Morley AA. Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients. Leukemia. 2013 Oct;27(10): 2105-2107. CIT 17
  96. Experts in Chronic Myeloid Leukemia, a group of more than 100 experts in chronic myeloid leukemia (CML). The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013 May 30;121(22): 4439-4442
  97. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013 Jul 25;122(4): 515-522 CIT 509
  98. Parker WT, Yeoman AL, Jamison BA, Yeung DT, Scott HS, Hughes TP, Branford S. BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance. Br J Cancer. 2013 Sep 17;109(6): 1593-1598. CIT 16
  99. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug 8;122(6): 872-884 CIT 1568
  100. Gallipoli P, Stobo J, Heaney N, Nicolini FE, Clark R, Wilson G, Tighe J, McLintock L, Hughes TP, Michor F, Paul J, Drummond M, Holyoake TL. Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. Br J Haematol. 2013 Dec;163(5): 674-676. CIT 4
  101. White DL, Eadie LN, Saunders VA, Hiwase DK, Hughes TP. Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells.2013 Leukemia 27 (5) 1201-4 CIT 10
  102. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes TP, Goldman JM, Shah NP, Kantarjian H; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 Nov: 369(19):1783-1796 CIT 738
  103. Hochhaus A, Saglio G, Larson RA, Kim D-W, Etienne G, Rosti G, De Souza C, Kurokawa M, Kalaycio ME, Hoenekopp A, Fan X, Shou Y, Kantarjian HM, Hughes TP. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vesus imatinib in patients with newly diagnosed chronic myeloid leukaemia in chronic phase. 2013 Blood 121(18):3703-8 CIT 88
  104. Branford S, Yeung D, Ross DM, Prime JA, Field CR, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Sullivan B, Briggs NE, Hertzberg M, Seymour JF, Reynolds J. Hughes TP. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1 the criteria for imatinib discontinuation in patients with CML. 2013 Blood 121(9):3818-3824 CIT 126
  105. Kok CH, Watkins DB, Leclercq T, D’Andrea R, Hughes TP, White DL. Low GFI1 expression in white blood cells of Cp-CML patients at diagnosis is strongly associated with subsequent blastic transformation. 2013 Leukaemia Jun;27(6):1427-1430 CIT 13
  106. Thomas D, Powell JA, Green BD, Barry EF, Ma Y, Woodcock J, Fitter S, Zannettino ACW, Pitson S, Hughes TP, Lopez AF, Shepherd PR, Wei AH, Ekert PG, Guthridge MA. Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival. 2013 PLOS Biology 11(3) e1001515 CIT 22
  107. Watkins DB, Hughes TP, White DL, D’Andrea RJ. NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis. Leukemia. 2013 Feb;27(2):489-90 CIT 10
  108. Vandyke K, Fitter S, Drew J, Fukumoto S, Schultz CG, Sims NA, Yeung DT, Hughes TP, Zannettino ACW. Prospective histomorphometric and DXA evaluation of bone remodelling in imatinib-treated CML patients: evidence for site-specific skeletal effects. 2012 J Clin Endocrinol Metab 98:67-76 IF 5.9 CIT 19
  109. Hiwase DK, Saunders VA, Nievergall E, Ross DM, White DL, Hughes TP. Dasatinib targets chronic myeloid leukaemia-CD34+ progenitors as effectively as it targets mature cells. 2012 Haematologica 98(6):896-900 IF 6.4 CIT 11
  110. Cortes J, Goldman JM, Hughes TP. Current issues in chronic myeloid leukaemia: monitoring, resistance and functional cure.2012 Journal of the National Comprehensive Cancer Network. 10(3): 1-20 IF 4.4 CIT 38
  111. Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, Schnittger S, Haferlach C, Gohring G, Proetel U, Kolb HJ, Krause SW, Hofmann WK, Schubert J, Einsele H, Dengler J, Hanel M, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Branford S, Hughes TP, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Saussele S, Hochhaus A and for the SAKK and the German CML study Group. Early molecular and cytogenetic response is predictive for long term progression-free and overall survival in chronic myeloid leukaemia. 2012 Leukemia 26(9)2096-2102 CIT 372
  112. Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, Flinn IW, Kurokawa M, Moiraghi B, Yu R, Blakesley RE, Gallagher NJ, Saglio G, Kantarjian HM. Nilotinib versus imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase: ENESTnd 3 year follow up. 2012 Leukemia 26(10):2197-2203 CIT 431
  113. Hiwase DK, Hughes TP. Sudden blast crisis in chronic myeloid leukaemia treated with tyrosine kinase inhibitors. 2012 Leukaemia Lymphoma 53(7): 1251-2 CIT 2
  114. Eadie LN, Saunders VA, Hughes TP, White DL. The degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2. 2012Leukaemia Lymphoma 54(3):569-578 CIT 19
  115. Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M, Pane F, Hughes TP, White DL, Radich J, Kim D-W, Saglio G, Cilloni D, Iacobucci I, Perini G, Woodman R, Cantelli-Forti G, Baccarani M, Hrelia P, Martinelli G. Association between imatinib transporters and metabolising enzymes genotype and response in newly diagnosed chronic myeloid leukaemia patients receiving imatinib therapy. 2012 Hematologica 98(2):193-200 IF 6.4 CIT 85
  116. Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim D-W, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukaemia in chronic phase: 48 month follow up results of a phase II study.2012 Leukemia 26(5):959-962 CIT 181
  117. Branford S, Kim D-W, Soverini S, Haque A, Shou Y, Woodman RC, Kantarjian HM, Martinelli G, Radich JP, Saglio G, Hochhaus A, Hughes TP, Muller MC. Initial molecular response at 3 months may predict both responses and event-free survival at 24 months in imatinib-resistant or intolerant patients with Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (CML-CP) treated with Nilotinib. 2012 J Clin Oncol 30:4323-4329t CIT 89
  118. Yin Oq, Giles FJ, Baccarani M, le Coutre P, Chiparus O, Gallagher N, Saglio G, Hughes TP, ochhh Hochhaus A, Kantarjian HM, Larson RA. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukaemia. 2012 Cancer Chemother Pharmacol 70(2):345-350 CIT 18
  119. Schafranek L, Leclercq TM, White DL, Hughes TP. Clarithrom ycin enhances dasatinib-induced cell death in CML cells, by inhibition of late stage autophagy. 2012 Leukaemia Lymphoma 54(1):198-201 CIT 31
  120. White DL, Radich J, Soverini S, Saunders VA, Frede AK, Dang P, Cilloni D, Lin P, Mongay L, Woodman R, Manley P, Slader C, Kim DW, Pane F, Martinelli G, Saglio G, Hughes TP. Chronic phase chronic myeloid leukaemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard –dose imatinib. 2012 Haematologica 97(6): 907-914 CIT 55
  121. Wang J, Hughes TP, Kok CH, Saunders VA, Frede A, Groot-Obbink K, Osborn M, Somogyi AA, D’Andrea RJ, White DL. Contrasting effects of dictofenac and ibuprofen on active imatinib uptake into leukaemic cells. 2012 British Journal of Cancer 106:1766-1771 CIT 18
  122. Blake S, Lyons AB, Hughes TP. Drug interaction studies evaluating T cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A. 2012 Experimental Haematology 40(8):612-621 CIT 14
  123. Larson RA, Yin OQP, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Dermirhan E, Hughes TP, Kantarijian, le Coutre P. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukaemia in chronic phase.2012 Eur J Clinical Pharma 68(5):723-733 IF 2.8 CIT 63
  124. Parker WT, Ho M, Scott HS, Hughes TP, Branford S. Poor response to second line kinase inhibitors in chronic myeloid leukaemia patients with multiple low level mutations, irrespective of their resistance profile. 2012 Blood 119:2234-2238 CIT 64
  125. Yeung D, Hughes TP. Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia. 2012 Critical Reviews in Oncogenesis 17(1) 17-30 IF 1.8 CIT 33
  126. Guilhot F, Hughes TP, Cortes J, Druker BJ, Baccarani M, Gathmann I, Hayes, M, Granvil C, Wang Y. Plasma exposure of imatinib and its correlation with clinical response in the tyrosine kinase inhibitor optimization and selectivity trial. 2012 Haematologica 97(5) 731-738 IF 6.4 CIT 64
  127. Branford S, Yeung DT, Prime JA, Choi S-Y, Bang J-H, Park JE, Kim D-W, Ross DM, Hughes TP. BCR-ABL1 doubling-times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold-rise: implications for monitoring and management. 2012 Blood 119(18)4264-4271 CIT 38
  128. Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, Cramer K, Reddy MR, Koptyra M, Penserga T, Glodkowska-Mrowka E, Bolton E, Holyoake TL, Eaves CJ, Cerny-Reiterer S, Valent P, Hochhaus A, Hughes TP, van der Kuip H, Sattler M, Wikto-Jedrzejczak W, Richardson C, Dorrance A, Stoklosa T, Williams DA. Rac2ndash; mitochondrial respiratory chain complex III-generated ROS cause genomic instability in chronic myeloid leukaemia stem cells and primitive progenitors. 2012 Blood 119(18)4253-4263 CIT 128
  129. White DL, Hughes TP. Classification of patients with CML basis of BCR-ABL transcript level at 3 months fails to identify patients with low OCT-1 activity destined to have poor imatinib response.2012 Journal of Clinical Oncology. 30(10)1144-1145 CIT 14
  130. Hercus T, Broughton S, Ekert H, Ramshaw M, Grimbaldeston M, Perugini M, Woodcock J, Thomas D, Pitson S, Hughes TP, D’Andrea R, Parker M, Lopez A. The GM-CSF receptor family: mechanism of activation and implications for disease. 2011 Growth Factors 30(2):63-75 CIT 46
  131. Hiwase DK, Hughes TP. Therapy of Advanced-Stage and Resistant Chronic Myeloid Leukemia. Leukemia. Principles and Practice of Therapy. Wiley-Blackwell ;281-295 DOI: 10.1002/9781444327359.ch23 2011
  132. Jabbour E, Saglio G, Hughes TP, Kantarjian H. Suboptimal responses in chronic myeloid leukaemia: implications and management strategies. 2011 Cancer 118(5):1181-91 CIT 20
  133. Tang M, Gonen M, Quintas-Cardama A, Cortes J, Kantarjian H, Field C, Hughes TP, Branford S, Michor F. Dynamics of chronic myeloid leukaemia response to long-term targeted therapy reveal treatment effects of leukaemic stem cells. Blood 2011 118:1622-1631 CIT 65
  134. Stein AM, Bottino D, Modur V, Branford S, Kaeda J, Goldman JM, Hughes TP, Radich JP. Hochhaus A. BCR-ABL transcripts dynamics support the hypothesis that leukaemic stem cells are reduced during imatinib treatment. Cancer Research 2011 17(21): 1-10 CIT 44
  135. Esposito N, Colavita I, Quintarelli C, Sica AR, Peluso AL, Luciano L, Picardi M, Del Vecchio L, Buonomo T, Hughes TP, White D, Radich JP, Russo D, Branford S, Saglio G, Melo JV, Martinelli R, Ruoppolo M, Kalebic T, Martinelli G, Pane F. SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukaemia. Blood 2011 118(13):3634-3644 CIT 44
  136. Kantarjian HM, Hochhaus A, Saglio G, Souza CD, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP, Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24 month minimum follow up of the phase-3 randomised ENESTnd trial. Lancet Oncology 2011 12(9):841-51 CIT 471
  137. Parker W, Lawrence RM, Ho M, Irwin DL, Scott H, Hughes TP, Branford S. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukaemia after imatinib resistance is predictive of outcome during subsequent therapy. 2011 Journal of Clinical Oncology 29(32) 4250-4259 CIT 92
  138. Tang C, Schafranek L, WatkinsDB, Parker WT, Moore S, Prime JA, White DL, Hughes TP. Tyrosine kinase inhibitor resistance in chronic myeloid leukaemia cell lines: Investigating resistance pathways. 2011 Leukaemia Lymphoma 52(11)2139-2147 CIT 67
  139. White DL, Hughes TP. Predicting the response of CML patients to tyrosine kinase inhibitor therapy. 2011 Current Haematology Malignancy Reports 6(2): 88-95 CIT 8
  140. Engler JR, Hughes TP, White DL. OCT-1 as a determinant of reponse to antileukemic treatment. 2011 Clin Pharmacol Ther 89(4):608-11 CIT 15
  141. Branford S, Hughes TP Mutational analysis in chronic myeloid leukaemia: when and what to do? Current Opinion in Hematology (-) 2011 18:111-116 CIT 26
  142. Cortes J, Hochhaus A, Hughes TP, Kantarjian H. Front line salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukaemia. J Clin Oncol (A*) 2011 29:524-531 CIT 93
  143. Kantarijian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim D-W, Shou Y, Gallagenr NJ, Blakesley, Baccarani M, Cortes J, le Coutre PD. Nilotinib is effective in patients with chronic myeloid leukaemia in chronic phase after imatinib resistance or intolerance: 24 month follow up results. Blood (A*) 2011 117(4):1141-1145 CIT 382
  144. Ross DM, Hughes TP, Melo JV. Do we have to kill the last CML cell? 2011 Leukemia (A*) 25(2):193-200 CIT 39
  145. Engler J, Zannettino ACW, Bailey CG, Rasko JEJ, Hughes TP, White DL. OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. Haematologica (B) 2011 96(2):213-220 CIT 22
  146. White DL, Saunders VA, Dang P, Engler J, Hughes TP. OCT-1 activity measurement provides a superior imatinib response predictor that screening for single-nucleotide polymorphisms of OCT-1. Leukemia (A*) 2010 24(11) 1962-1965 CIT 48
  147. White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Wang YL, Branford S, Mueller M, Beaufils N, Beillard E, Colomer D, Dvorakova D, Ehrencrona H, Goh HG, El Housni H, Jones D, Kairisto V, Kamel-Reid S, Kim DW, Langabeer S, Ma ESK, Press RD, Romeo G, Wang L, Zoi K, Hughes TP, Saglio G, Hochhaus A, Goldman JM, Metcalfe P, Cross NCP. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood Nov 2010 116(19) 111-117 CIT 132
  148. Engler J, Frede A, Saunders V, Zannettino ACW, White DL, Hughes TP. The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake into their CD34+ cells. Blood (A*) 2010 116:2776-2778 CIT 24
  149. Ross DM, Branford S, Seymour JF, Schwarer AP, Aruthur A, Bartley PA, Slader C, Field C, Dang P, Filshie RJ, Mills A K, Grigg AP, Melo J, Hughes TP. Patients with chronic myeloid leukaemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukaemia by DNA PCR. Leukemia (A*) 2010 24 1719-1724 CIT 261
  150. Hughes TP, Hochhaus A, Branford S, Muller MC, Kaeda J, Foroni L, Druker B, Guilhot F, Larson RA, O’Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, Radich JP. Long term prognostic significance of early molecular response to imatinib in new diagnosed chronic myeloid leukaemia: an analysis from the international randomized study of interferon versus STI571 (IRIS). Blood 2010 116 (19) 3758-3765 CIT 521
  151. Fraser C, Brown M, Diener K, Guerin L, Hughes TP, Lousberg ER, Hayball JD. Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo. Cancer Biology & Therapy (A) 2010 10(7): 715-727 CIT 12
  152. Bartley PA, Ross DM, Latham S, Martin-Harris MH, Budgen B, Wilczek V, Branford S, Hughes TP, Morley AA. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA. Int J Hematol (B) 2010 32(6 Pt1):222-228 Cit 49
  153. Eadie L, Hughes TP, White DL. Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells. Leukemia (A*) 2010 24(4)855-7 CIT 14
  154. White DL, Dang P, Engler J, Frede A, Zrim S, Osborn M, Saunders VA, Manley PW, Hughes TP. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukaemia treated with imatinib. J Clin Oncol (A*) 2010 28:2761-2767 CIT 189
  155. Saglio G, Kim D-W, Issaragrisil S, Le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM the ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukaemia. N. Engl J Med (A*) 2010 362:2251-2259 CIT 1565
  156. Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino ACW. Plasma adiponectin levels are markedly elevated in Imatinib-treated Chronic Myeloid Leukaemia (CML patients): A mechanism for improved insulin sensitivity in type 2 diabetic CML patients? J Clin Endocinol Metab.(A*) 2010 95 (8) 3763-3767 CIT 43
  157. Hiwase DK, White D, Zrim S, Saunders V, Melo JV, Hughes TP. Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy 2010 Leukemia (A*) 24: 658-660; CIT 35
  158. Osborn M, Hughes TP. Managing imatinib resistance in chronic myeloid leukaemia. 2010 Current Opinions in Hematology 17:97-103 CIT 16
  159. Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim D-W, Pane F, Pasquini R, Goldberg SL, Kalaycio M, Moiraghi B, Rowe JM, Tothova, De Souza C, Rudoltz M, Yu R, Krahnke T, Kantarjian HM, Radich JP, Hughes TP. Phase III randomized open label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukaemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. 2010 Journal of Clinical Oncology (A*) 28(3):424-430. CIT 284
  160. Hiwase DK, White DL, Powell JA, Saunders VA, Zrim SA, Frede AK, Guthridge MA, Lopez AF, D’Andrea RJ, To LB, Melo JV, Kumar S, Hughes TP. Blocking cytokine signalling along with intense BCR-ABL kinase inhibition induces apoptosis in primary CML progenitors. 2010 Leukemia (A*) 24(4) 771-8 CIT 58
  161. Branford S, Hughes TP. Practical considerations for monitoring patients with chronic myeloid leukaemia 2010 Seminars in Hematology (A) 47(4) 327-334 CIT 14
  162. Engler JR, Frede A, Saunders VA, Zannettino ACW, Hughes TP, White DL. Chronic myeloid leukaemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. 2010 Leukemia (A*) 24(4): 765-70 CIT 66
  163. Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino ACW. Dysregulation of bone remodelling by imatinib mesylate. 2010Blood (A*) 115 766-774 CIT 114
  164. Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP, Hayball JD. Dasatinib inhibits recombinant viral antigen-specific murine CD4(+) and CD8(+) T-cell responses and NK-cell cytolytic activity in vitro and in vivo. 2009 Experimental Haematology (A) 37(2) 256-265 CIT 60
  165. Fraser CK, Lousberg EL, Kumar R, Hughes TP, Diener K, Hayball JD. Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo. 2009 Exp Hematol (A) 37(12) 1435-44 CIT 41
  166. Kantarjian H, Pasquini R, Levy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes TP, Bleickardt E, Dejardin D, Cortes J, Shah NP. Dasatinib or high-dose imatinib for chronic phase chronic myeloid leukaemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two year follow up of a randomized phase 2 study (START-R). 2009 Cancer (A) 115(18) 4136-4147 CIT 255
  167. Hughes TP, Branford S. Measuring minimal residual disease in chronic myeloid leukaemia: fluorescence in-situ hybridization and polymerase chain reaction. 2009 Clinical Lymphoma & Myeloma (B) 9:(3) 266-271 CIT 9
  168. Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukaemia patients after imatinib failure – does the BCR-ABL mutation status really matter. 2009 BLOOD 114 (27) 5426-5435 CIT 198
  169. Ross DM. Branford S, Melo JV, Hughes TP. Reply to ‘What do we mean by sensitivity when we talk about detecting minimal residual disease?’ by Steinbach and Debatin (letter) 2009 Leukemia 23 (4) 819-820 CIT 12
  170. Ross DM, Schfranek L, Hughes TP, Nicola M, Branford S, Score J. Genomic translocation breakpoint sequences are conserved in BCR-ABL1 cell lines despite the presence of amplification (letter). 2009 Cancer Genet Cytogenet (B) 189(2) 138-9 CIT 7
  171. Drummond MW, Heaney N, Kaeda J, Nicolini FE, Clark RE, Wilson G, Shepherd P, Tighe J, McLintock L, Hughes TP, Holyoake TL. A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patiens who have achieved a complete cytogenetic response (letter). 2009 Leukemia 23(6) 1199-1201 CIT 47
  172. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger F, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes TP, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R. Chronic myeloid leukaemia. An update of concepts and management recommendations of European LeukemiaNet.2009 Journal of Clinical Oncology 27 (35) 6041-51 CIT 1488
  173. Muller MC, Cortes JE, Kim D-W, Druker BJ, Erben P, Pasquini R, Branford S, Hughes TP, Radich JP, Ploughman L, Mukhopadhyay J, Hocchaus A. Dasatinib treatment of chronic phase chronic myeloid leukaemia: analysis of responses according to pre-existing BCR-ABL mutations. 2009 Blood 114(24) 4944-4953 CIT 294
  174. Hochhaus A, O’Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Muller MC, Radich JP, Rudoltz M, Mone M, Gathmann, Hughes TP, Larson RA, IRIS Investigators. Six-year follow up of patients receiving imatinib for the first-line treatment of chronic myeloid leukaemia. 2009 Leukemia 23(6) 1054-61 CIT 949
  175. White DL, Hughes TP. Predicting the response of CML patients to tyrosine kinase inhibitor therapy. 2009 Current Hematologic Malignancy Reports 4(2) 59-65 CIT 10
  176. Hochhaus A, Muller M, Radich J, Branford S, Kantarjian HM, Hanfstein B, Rousselot P, Kim DW, Lipton JH, Bleickardt E, Lambert A. Hughes TP. Dasatinib-associated major molecular responses in patients with chronic myeloid leukaemia in chronic phase following imatinib failure: response dynamics and predictive value. 2009 Leukemia 23(9): 1628-33 CIT 50
  177. Hughes TP, Saglio G, Branford S, Soverini S, Kim D-W, Muller MC, Martinelli G, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, Radich J, Hochhaus A. Impact of baseline BCR-ABL mutations on response to Nilotinib in patients with chronic myeloid leukaemia in chronic phase. 2009 Journal of Clinical Oncology 27(25) 4204-10 CIT 327
  178. Tojo A, Usuki K, Urabe A, Maeda Y, Kobayashi Y, Jinnai I, Ohyashiki K, Nishimura M, Kawaguchi T, Tanaka H, Miyamura K, Miyazaki Y, Hughes TP, Branford S, Okamoto S, Ishikawa J, Okada M, Usui N, Tanii H, Amagasaki T, Natori H, Naoe T. A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or –intolerant Ph+ CML or relapsed/refractory Ph+ ALL. International Journal of Hematology May 2009 89 (5) 679-688 CIT 39
  179. Vandyke K, Dewar AL, Farrugia AN, Fitter S, Bik To L, Hughes TP, Zannettino ACW. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 2009/5/1 23(5) 994-997 CIT 51
  180. Hiwase DK, White DL, Saunders VA, Kumar S, Melo JV, Hughes TP. Short term intense BCR-ABL kinase inhibition with Nilotinib is adequate to trigger cell death in BCR-ABL+ cells. 2009 Leukaemia 23 (6)1205-1207 CIT 17
  181. Vandyke K, Dewar AL, Fitter S, Menicanin D, To LB, Hughes TP, Zannettino ACW. Imatinib mesylate causes growth plate closure in-vivo. 2009 Leukemia (A*) 23(11) 2155-2159 CIT 51
  182. Viswanathan S, Powers JT, Einhorn W, Hoshida Yujin, Ng T, Toffanin S, O’Sullivan M, Lu J, Philips LA, Lockhart VL, Shah SP, Tanwar PS, Mermel CH, Beroukhim R, Azam M, Teixeira J, Meyerson M, Hughes TP, Llovet JM, Radich J, Mullighan CG, Golub TR, Sorensen PH, Daley GQ. Lin28 enhances tumorigenesis and is associated with advanced human malignancies. 2009 Nature Genetics 41(7) 843-8 CIT 686
  183. Hughes TP, Hochhaus A. Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy.2009 Seminars in Hematology (A) 46(2) Supp 3:S11-S15 CIT 5
  184. Blake SJ, Lyons AB, Hughes TP. Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro. J Cell Mol Med (-) 2008 13(3) CIT 32
  185. Apperley J, Cortes JE, Dong-Wook K, Roy L, Roboz GJ, Rosti G, Bullorsky E, Abruzzese E, Hochhaus A, Heim D, de Souza CA, Larson RA, Lipton JH, Khoury HJ, Hyeoung-Joon K, Sillaber C, Hughes TP, Erben P, Van Tornout JMA, Stone RM. Dasatinib in the treatment of chronic myeloid leukaemia in accelerated phase after imatinib failure: The Start A trial. 2009 Journal of Clinical Oncology 27(21) 3472-3479 CIT 196
  186. Khoury HJ, Guilhot F, Hughes TP, Kim D-W, Cortes J. Dasatinib treatment for Philadelphia chromosome-positive leukaemias: practical considerations. 2008 Cancer 115(7) 1381-94 CIT 50
  187. Cross NC, Daley GQ, Green AR, Hughes TP, Jamieson C, Manley P, Mughai T, Perrotti D, Radich J, Skoda R, Soverini S, Vainchenker W, Verstovsek S, Villeval JL, Goldman JM. BCR-ABL1-positive CML and BCR-ABL1- negative chronic myeloproliferative disorders: some common and contrasting features. Leukemia 2008 22(11) 1975-1989 CIT 33
  188. Hughes TP, Branford S White DL, Reynolds J, Koelmeyer, Seymour JF, Taylor K, Arthur C, Schwarer A, Morton J, Cooney J, Leahy MF, Rowling P, Catalano J, Hertzberg M, Filshie R, Mills AK, Fay K, Durrant S, Januszewicz, Joske D, Underhill C, Dunkley S, Lynch K, Grigg A on behalf of the Australasian Leukaemia and Lymphoma Group. Impact of early dose intensity on cytogenetic and molecular responses in chronic phase CML patients receiving 600 mg/day. 2008 Blood 112(10) 3965-3973 CIT 170
  189. Giles FJ, DeAngelo DJ, Baccarani M, Deininger M, Guilhot F, Hughes TP, Mauro M, Radich J, Ottmann O, Cortes J. Optimizing outcomes for patients with advanced disease in chronic myelogenous leukaemia. 2008 Semin Oncol (A) 35(Supp1):S1-17; quiz S18-20. CIT 38
  190. Branford S, Fletcher L, Cross NC, Muller MC, Hochhaus A, Kim DW, Radich JP, Saglio G, Pane F, Kamel-Reid S, Wang YL, Press RD, Lynch K, Rudzki Z, Goldman JM, Hughes TP. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. 2008 Blood 112(8)3330-3338 CIT 355
  191. Hui CH, Sia H, Mangos H, Horvath N, Lee H, Lewis I, Hughes TP, To LB, Bardy P. Daclizumab has poor efficacy in steroid-refractory severe acute graft-versus-host disease: a single centre experience with 12 allograft patients. 2008 Bone Marrow Transplantation (B) 41:409-410 CIT 4
  192. Ross D, Hughes TP. How complete is ‘complete’ molecular response in imatinib-treated CML? (invited commentary) 2008 Leukemia and Lymphoma (B) 49(7)1230-1231 CIT 5
  193. Ross D, Watkins D, Hughes TP, Branford S. Reverse transcription with a random pentadecamen primer increases the detection limit of quantitative PCR for BCR-ABL in chronic myeloid leukaemia: implications for defining the sensitivity of minimal residual disease. 2008 Clinical Chemistry (B) 54:1568-1571 CIT 17
  194. Ross D, Hughes TP. Current and emerging tests for the laboratory monitoring of chronic myeloid leukaemia and related disorders. 2008 Pathology (B) 40(3)231-246 CIT 19
  195. Fitter S, Dewar A, Kosatakis P, To LB, Hughes TP, Roberts M, Lynch K, Vernon-Roberts B, Zannettino ACW. Long term imatinib therapy promotes bone formation in CML patients. 2008 Blood 111(5) 2538-2547 CIT 162
  196. Hiwase D, Saunders V, Hewett D, Frede A, Zrim S, Dang P, Eadie L, To LB, Melo J, Kumar S, Hughes TP, White D. Dasatinib cellular uptake and efflux in chronic myeloid leukaemia. Cells: Therapeutic Implications. 2008 Cancer Therapy: Clinical (A) 14(12) 3881-3888 CIT 190
  197. Hochhaus A, Baccarani M, Deininger M, Apperley J, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukaemia in chronic phase with resistance or intolerance to imatinib. 2008 Leukaemia 22(3) 1200-1206 CIT 439
  198. Shah N, Kantarijian M, Dong-Wook K, Rea D, Dorlhiac-Llacer, Milone J, Vela-Ojeda J, Silver R, Khoury J, Charbonnier A, Khoroshko N, Paquette R, Deninger M, Collins R, Otero I, Hughes TP, Bleickardt E, Strauss L, Francis S, Hochhaus A. Intermittent target inhibition with Dasatinib (100 mg once daily) preserves efficacy and improves tolerability in imatinib-resistant and intolerant-chronic-phase chronic myeloid leukaemia. 2008 Journal of Clinical Oncology 26(19) 3204-3212 CIT 526
  199. Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D, Hughes TP, Le Beau MM, Pui C_H, Relling MV, Shurtleleff SA, Downing JR. BCR-ABL1 lymphoblastic leukaemia is characterised by the deletion of Ikaros. 2008 Nature 453(7191) 110-4 CIT 901
  200. Blake S, Hughes TP, Mayrhofer G, Lyons AB. The SRC/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. 2008 Clin Immunol (C) 127(3):330-339 CIT 91
  201. Le Coutre P, Ottmann O, Giles F, Dong-Wook K, Coretes J, Gattermann N, Apperley J, Larson R, Abruzzese E, O’Brien S, Kuliczkowski K, Hochhaus A, Mahon FX, Saglio G, Gobbi M, Yok-Lam K, Baccarani M, Hughes TP, Martinelli G, Radich G, Zheng M, Shou Y, Kantarijian H. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or intolerant accelerated phase chronic myelogenous leukaemia. 2008 Blood 111(4)1834-1839 CIT 342
  202. Blake SJ, Lyons AB, Fraser CK, Hayball JD, Hughes TP. Dasatinib suppresses in vitro killer cell cytotoxicity (letter). 2008Blood 111(8) 4415-4416 CIT 78
  203. Cross NC, Hughes TP, Hochhaus A, Goldman JM. International standardisation of quantitative real-time RT-PCR for BCR-ABL (letter). 2007 Leukemia Research (B) 32(3) 505-506 CIT 33
  204. Hughes TP. Is drug treatment superior to allografting as first line therapy in chronic myeloid leukaemia. 2007 Nature Clinical Practice Oncology (C) 5(1)14-15 CIT 1
  205. Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K, Hughes TP. BCR-ABL mRNA levels continue to decline in patients with chronic phase chronic myeloid leukaemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. 2007 Clinical Cancer Research 13(23)7080-7085 CIT 149
  206. White DL, Saunders VA, Quinn SR, Manley PW, Hughes TP. Imatinib increases the intracellular concentration of nilotinib which may explain the observed synergy between these drugs (letter). 2007 Blood 109:3609-10 CIT 52
  207. White DL, Saunders V, Dang P, Engler J, Venable A, Zrim S, Zannettino A, Lynch K, Manley P, Hughes TP. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity. Higher doses of imatinib may overcome the negative impact of low OCT-1 activity. 2007 Blood 110(12) 4064-4072 CIT 337
  208. White DL, Saunders V, Grigg A, Arthur C, Filshie R, Leahy MF, Lynch K, To LB, Hughes TP. Measurement of in-vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in CML. 2007 Journal of Clinical Oncology 25(28) 4445-4451 CIT 69
  209. Branford S, Hughes TP, Milner A, Koelmeyer R, Schwarer A, Arthur C, Filshie R, Moreton S, Lynch K, Taylor K.. Efficacy and safety of imatinib in patients with chronic myeloid leukaemia and complete or near-complete cytogenetic response to interferon-alpha. 2007 Cancer (A) 110(4) 801-808 CIT 11
  210. Hughes TP, Branford S. Ph++ ALL: resistance seeds sown early. Inside Blood Capsule. 2007 Blood (A*) 110 (2): 472
  211. Shah NP, Skaggs B, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. 2007 Journal of Clinical Investigation 117(9) 2562-2569 CIT 381
  212. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, Robak T, Khoroshko N, Masszi T, Skotnicki A, Hellmann A, Zaritsky A, Golenkov A, Radich J, Hughes TP, Countouriotis A, Shah N. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukaemia after failure of first-line imatinib: a randomised phase-II trial. 2007 Blood 109(12) 5143-5150 CIT 474
  213. Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukaemia after failure of imatinib therapy. 2007 Blood 109(6) 2303-2309 CIT 709
  214. Hughes TP, Branford S, Goldman J. Response: reliability of PCR for BCR-ABL transcripts. 2007 Blood (A*) 109:2263-2264
  215. Druker B, Guilhot F, O’Brien S, Gathman I, Kantasrjian H, Gattermann N, Deininger M, Silver R, Goldman J, Stone R, Cervantes F, Hochhaus A, Powell B, Gabrilove J, Rousselot P, Reiffers J, Cornelissen J, Hughes TP, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen J, Radich J, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson R. Five-year follow up of patients receiving Imatinib for chronic myeloid leukaemia. 2006 New England Journal of Medicine 355 (23) 2408-2417 CIT 3556
  216. Luke C, Nguyen AM, To LB, Seshadri R, Hughes TP, Bardy P, Colbeck M, Buranyi-Trevarton D, McMellon M, Roder D. Myeloid leukaemia and treatment and survival – the South Australian Experience 1977 – 2002. 2006 Asian Pacific J Cancer Prev (7): 227-233 CIT 6
  217. Branford S, Cross NC, Hochhaus A, Radich J, Saglio, Kaeda J, Goldman J, Hughes TP. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. 2006 Leukaemia 20(11) 1925-30 CIT 195
  218. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes TP, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann. Evolving concepts in the management of chronic myeloid leukaemia: recommendations from an expert panel on behalf of the European Leukaemia Net. 2006 Blood 108(6) 1809-1820 CIT 1547
  219. Grigg A, Hughes TP. Role of allogeneic stem cell transplantation for adult chronic myeloid leukaemia in the imatinib era. 2006 Biol Blood Marrow Transplant 12(8) 795-807 CIT 36
  220. Hui C-H, Hughes TP. Autologous stem cell collection and autograft for patients with chronic myeloid leukaemia in the era of ABL kinase inhibitors: back to the bench. 2006 Leukaemia and Lymphoma (B) 47(9) 1721-3 CIT 1
  221. Hughes TP, Deininger MW, Hochhaus A, Branford S, Radich JP, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman J. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors – Review and recommendations for ‘harmonizing’ current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. 2006 Blood 108(1) 28-37 CIT 1236
  222. White DL, Saunders VA, Dang P, Engler J, Zannettino ACW, Cambareri AC, Quinn SR, Manley PW, Hughes TP. OCT-1 mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107); reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. 2006 Blood 108(2) 697-704 CIT 470
  223. Ross DM, Branford S, Moore S, Hughes TP, Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. 2006 Leukemia 20(4) 664-70 CIT 100
  224. Dewar AL, Farrugia AN, Condina MR, To LB, Hughes TP, Vernon-Roberts B, Zannettino ACW. Imatinib as a potential anti-resorptive therapy for bone disease. 2006 Blood 107(11) 4334-4337 CIT 85
  225. Hughes TP, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. 2006 Blood Reviews 20, 29-41 CIT 179
  226. Michor F, Hughes T, Iwasa Y, Branford S, Shah N, Sawyers C, Nowak A. Dynamics of chronic myeloid leukaemia. 2005 Nature 435(7046) 1267-70 June 30 CIT 813
  227. White D, Saunders V, Lyons AB, Branford S, Grigg A, To LB, Hughes TP. In-vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in de-novo CML patients. 2005 Blood 106(7) 2520-2526 CIT 166
  228. Dewar A, Zannettino ACW, Hughes TP, Lyons AB. Inhibition of c-fms by Imatinib – Expanding the spectrum of treatment. 2005 Cell Cycle 4(7) 38-40 CIT 59
  229. Dewar A, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the functional capacity of cultured human monocytes. 2005 Immunol Cell Biol (B) 83(1)48-56 CIT 47
  230. Dewar A, Cambareri A, Zannettino ACW, Miller B, Doherty K, Hughes TP, Lyons B. Macrophage colony stimulating factor receptor, c-fms, is a novel target of imatinib. 2005 Blood 105(8) 3127-3132 CIT 307
  231. Mollee P, Arthur C, Hughes TP, Januszewicz H, Grigg A, Bradstock K, Wolf M, Gibson J, Schwarer AP, Spencer A, Browett P, Hawkins T, Seldon M, Herrmann R, Watson A, Seymour JF, Martin N, Shina S, Low C, Wright S, Rodwell R, Coulston J, Morton J, Blacklock H, Taylor D, Taylor KM. Interferon--2B and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia. 2004 Annals of Oncology 15(12) 1810-1815 CIT 6
  232. Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour J, Durrant S, Browett P, Schwarer A, Arthur C, Catalano J, Leahy M, Filshie R, Bradstock K, Herrmann R, Joske D, Lynch K, Hughes TP. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. 2004 Blood 104(9) CIT 268
  233. Mullighan C, Heatley S, Doherty K, Szabo F, Grigg A, Hughes TP, Schwarer A, Szer J, Tait B, To LB, Bardy P. Non-HLA immunogenetic polymorphisms and the risk of complications following allogeneic haemopoietic stem cell transplantation.2004 Transplantation 27(4) 587-596. CIT 90
  234. Szer J, Durrant S, Schwarer AP, Bradstock KF, Gibson J, Arthur C, To LB, Hughes TP, Raunow H. Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation. 2004 Int Med J 34(3) 98-102 CIT 11
  235. Roberts MM, Dyson P, Rawling C, Thorp D, Rawling T, White D, Horvath N, Bardy P, Hui CH, Dart GW, To LB, Hughes TP. Selected CD34 blood cell allografts for older patients: low transplant-related mortality, graft failure and acute GvHD. 2003 Cytotherapy Vol 5, No 6, 534-541 CIT 3
  236. Branford S, Rudzki Z, Harper A, Grigg A, Taylor K, Durrant S, Arthur C, Browett P, Schwarer AP, Ma D, Seymour JF, Bradstock K, Joske D, Lynch K, Gathmann I, Hughes TP. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. 2003 Leukemia, 17(12) 2401-2409 CIT 179
  237. Dewar AL, Domaschenz RM, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the in vitro development of the onocyte/macrophage lineage from normal human bone marrow progenitors. 2003 Leukemia 17(9):1713-1721 CIT 63
  238. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Henslee ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM and Radich J. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed patients with chronic myeloid leukemia. 2003 New England Journal of Medicine 349(15) 1423-1432 CIT 1404
  239. Hui CH, Goh KY, White DL, Branford S, Grigg A, Seymour JF, Kwan YL, Walsh S, Hoyt R, Trickett A, Rudzki B, Ma DDF, To LB, Hughes TP. Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. 2003 Leukemia 17(5) 821-828 CIT 51
  240. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, Taylor K, Herrmann R, Seymour J, Arthur C, Joske D, Lynch K, Hughes TP. The detection of BCR-ABL mutations in imatinib-treated CML patients is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. 2003 Blood 102: 276-283. CIT 869
  241. O’Brien SG, Guilhot F, Larson R A, Gathmann I, Baccarani M, Cervantes F, Cornelissen J, Fischer T, Hochhaus A, Hughes TP, Lechner K, Nielsen J, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman J, Kantarjian, Taylor K, Verhoef G, Bolton A, Capdeville R, Druker B. Imatinib compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia. 2003 New England Journal of Medicine 348(110 994-1004 CIT 3740
  242. Borg M, Hughes TP, Horvath N, Rice M, Thomas AC. Renal toxicity after total body irradiation 2002 International Journal of Radiation Oncology Biology Physics 54(4): 1165-1173 CIT 56
  243. Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamemberane mutant V560Gkit is more sensitive to imatinib (STI571) compared to wild-type c-KIT whereas the kinase domain mutant D816Vkit is resistant. 2002 Molecular Cancer Therapeutics 1(12) 1115-1124 CIT 273
  244. Mullighan CG, Heatley S, Doherty K, Szabo F, Grigg A, Hughes TP, Schwarer AP, Szer J, Tait BD, Bik To L, Bardy PG. Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. 2002 Blood 99(10) 3524-3529 CIT 236
  245. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch KP, Hughes TP. High Frequency of Point Mutations Clustered Within the ATP Binding Region of BCR/ABL in CML and Ph-positive ALL Patients who Develop Imatinib (STI571) Resistance. 2002 Blood 99(9) 3472-3475 CIT 813
  246. Branford S, Hughes TP, Rudzki Z. Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in CML is confined to patients with a linked polumorphism within the BCR gene. 2002 British Journal of Haematology 117:875-877 CIT 30
  247. Lutwyche JK, Keough RA, Hughes TP, Gonda TJ. Mutation screening of the c-MYB negative regulatory domain in acute and chronic myeloid leukaemia. 2001 British Journal of Haematology 114(3)632-634 CIT 13
  248. Hui CH, Bardy P, Hughes TP, Horvath N, To LB. Successful salvage of RAEB/AML relapsing early post allograft with FLAG-Ida conditioned mini-allograft: a report of two cases. 2001 Clinics in Laboratory Haematology 23, 135-138 CIT 1
  249. Craddock C, Bardy P, Kreiter S, Johnston R, Apperley J, Marks D, Huber C, Kolbe K, Goulding R, Lawler M, Goldman J, Hughes TP, Derigs G. Engraftment of T-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen. 2000 British Journal of Haematology 111(3) 797-800 CIT 29
  250. Szabo F, Horvath N, Seimon S, Hughes TP. Inappropriate antidiuretic hormone secretion, abdominal pain and disseminated varicella-zoster virus infection: an unusual triad in a patient 6 months post mini-allogeneic peripheral stem cell transplant for chronic myeloid leukaemia. 2000 Bone Marrow Transplant, 26(2) 231-3 CIT 26
  251. Branford S, Rudzki Z, Hughes TP. A novel BCR-ABL transcript (e8a2) with the inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemia. 2000 Br J Haematol, 109(3) 635-637 CIT 40
  252. Moore S, McDiarmid L, Hughes TP. Stem cell factor and chronic myeloid leukaemia. 2000 Leukaemia and Lymphoma 38:211-220 CIT 5
  253. Grigg AP, Szer J, Beresford J, Dodds A, Bradstock K, Durrant S, Schwarer AP, Hughes TP, Herrmann R, Gibson J, Arthur C, Mathews J. Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. 1999 Br J Haematol, 107(2) 409-418 CIT 89
  254. Branford S, Hughes TP, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. 1999 Br J Haematol 107(3) 587-599 CIT 283
  255. Moore S, Haylock DN, Levesque J-P, McDiarmid L, Samels L, To LB, Simmons PJ, Hughes TP. Stem cell factor as a single agent induces marked proliferation of the Philadelphia chromosome positive fraction of CML CD34+ cells. 1998 Blood 92: 2461-2470 CIT 53
  256. Lewis ID, McDiarmid LA, Samels LM, To LB, Hughes TP. Establishment of a reproducible model of chronic phase chronic myeloid leukemia in NOD/SCID mice using blood derived mononuclear or CD34 positive cells. 1998 Blood 91: 630-640. CIT 84
  257. Iverson PO, Lewis ID, Turczynowicz S, Hasle H, Niemeyer C, Schmiegelow K, Bastiras S, Biondi A, Hughes TP, Lopez AF. Inhibition of granulocyte-macrophage colony-stimulating factor prevents dissemination and induces remission of juvenile myelomonocytic leukemia in engrafted immunodeficient mice. 1997 Blood 90(12) 4910-4917 CIT 54
  258. White DL, Hutchins CJ, Turczynowicz S, Suttle J, Haylock DN, Hughes TP, Juttner CA, To LB Detection of minimal residual disease in an AML patient with trisomy 8 using interphase FISH. 1997 Pathology 29(3) 289-293 CIT 11
  259. Lewis ID, Haylock DN, Moore S, To LB, Hughes TP. Peripheral blood is a source of BCR-ABL negative pre-progenitors in early chronic phase chronic myeloid leukemia. 1997 Leukemia 11(4) 581-587. CIT 12
  260. Hughes TP, Grigg A, Szer J, Ho J, Dale BM, Green RM, Norman JE, Sage RE, Herrmann R, Cannell P, Schwarer AP, Taylor K, Atkinson K, Arthur C. Mobilisation of predominantly Philadelphia chromosome-negative progenitors using cyclophosphamide and rHu G-CSF in early chronic phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control. 1997 Br J Haematol 96(3) 635-640. CIT 21
  261. Lewis ID, Haylock DN, Moore S, To LB, Juttner CA, Hughes TP. Identification of normal primitive progenitors in blood and mobilised blood in chronic myeloid leukaemia. 1995. Blood 86(10):2085-2085. CIT 1
  262. White DL, Hutchins CJ, Haylock DN, Turczynowicz S, Bishop A, To LB, Hughes TP, Juttner CA. Direct analysis of FACS sorted hemopoietic cell fractions using FISH. 1995 Biotechniques 18: 818-821 CIT 6
  263. Kumar S, White DL, Takai S, Turczynowicz S, Juttner C, Hughes TP. Apoptosis regulatory gene NEDD2 maps to human chromosome 7q34-35, a region frequently affected in haematological neoplasms. 1995 Human Genet 95: 641-644 CIT 34
  264. Orr SL, Hughes TP, Sawyers CL, Kato RM, Quan SG, Williams SP, Witte ON, Hood LE. Isolation of unknown genes from human bone marrow by differential screening and single-pass eDNA sequence determination. 1994 Proc Natl Acad Sci USA 91(25)11869-11873. CIT 19
  265. Cross NCP, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. 1993 Blood 82(6) 1929-16 CIT 426
  266. Marks DI, Cullis JO, Ward K, Lacey S, Szydlo R, Hughes TP, Schwarer AP, Mackinnon S, Barrett AJ, Hows JM, Goldman JM. Bone marrow transplantation for chronic myeloid leukaemia using sibling and volunteer unrelated donors: a comparison of complications in the first two years. 1993 Ann Int Med 119(3) 207-214 CIT 221
  267. Cross NCP, Hughes TP, Lin F, O'Shea P, Bungey J, Marks DI, Ferrant A, Martiat P, Goldman JM. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. 1993 Br J Haematol 84(1) 67-74 CIT 173
  268. Cullis JO, Szydlo RM, Cross NC, Marks DI, Schwarer AP, Hughes TP, Mackinnon S, Hale G, Waldmann H, Hows JM, Goldman JM. Matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia in chronic phase: comparison of ex-vivo and in vivo T-cell depletion. 1993 Bone Marrow Transplant 11: 107-111 CIT 15
  269. Marks DI, Hughes TP, Szydlo R, Kelly S, Cullis JO, Schwarer AP, Mackinnon S, Apperley J, Barret J, Hows JM, Goldman JM. HLA-identical sibling donor marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome. 1992 Br J Haematol 81(3) 383-390. CIT 39
  270. Cullis JO, Schwarer AP, Hughes TP, Hows JM, Franklin I, Morgenstern G, Goldman JM. Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted donor marrow: feasibility of using busulphan alone for reconditioning. 1992 Br J Haematol 80(1) 33-39 CIT 49
  271. Cullis JO, Jiang YZ, Schwarer AP, Hughes TP, Barrett AJ, Goldman JM. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. 1992 Blood 79(5) 1379-1381. CIT 167
  272. Bi S, Hughes TP, Bungey J, Chase A, de Fabritiis P, Goldman JM. P 53 in chronic myeloid leukemia cell lines. 1992 Leukemia 6(8) 839-842. CIT 64
  273. Hughes TP, Ambrosetti A, Barbu V, Bartram C, Battista R, Biondi A, Chiamenti A, Cimino G, Ernst P, Frassoni F, Gasparini G, Gentilini A, Gluckman E, Grosveld G, Guerrasio A, Hegewich S, Janssen JWG, Keating A, Lo Coco F, Martiat P, Martinelli G, Mills K, Morgan G, Nadali G, Pelicci PG, Perona P, Pignatti PF, Richard P, Saglio G, Trabetti M, Turco A, Veneri D, Zaccaria A, Zander A, Goldman JM. 1991. Clinical value of PCR in diagnosis and follow-up of leukaemia and lymphoma: Report of the third workshop of the molecular biology/BMT Study Group. Leukemia 5(6) 448-451 CIT 22
  274. Hughes TP, Morgan GJ, Martiat P, Goldman JM. Detection of residual leukaemia after bone marrow transplantation for chronic myeloid leukaemia: role of PCR in predicting relapse. 1991. Blood 77(4) 874-878 CIT 278
  275. Goldman JM, Hughes TP. Detection and significance of minimal residual disease in patients with leukaemia and lymphoma. Bone Marrow Transplantation 1991 Vol 7 66-69 CIT 3
  276. Hughes TP, Goldman JM. Improved results with PCR for CML (letter). 1990 Lancet 336(8718)812 CIT 13
  277. Hughes TP, Janssen JWG, Morgan G, Martiat P, saglio G, Pignon JM, Pignatti FP, Mills K, Keating A Gluckman E, Bartram CR, Goldman JM. False positive results with PCR to detect leukaemia-specific transcript (letter) 1990 Lancet 335(8696)1037-1038 CIT 66
  278. Morgan GJ, Hernandez A, Chan LC, Hughes TP, Martiat P, Wiedemann LM. The role of alternative splicing patterns of BCR/ABL transcripts in the generation of the blast crisis of chronic myeloid leukaemia. 1990 British Journal of Haematology 76(1) 33-38 CIT 40
  279. Kaminski E, Hows J, Man S, Brooks P, Mackinnon S, Hughes TP, Avakian O, Goldman JM, Batchelor JR. Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. 1990 Transplantation 48(4) 608-613. CIT 195
  280. Mackinnon S, Hows JM, Goldman JM, Arthur CK, Hughes TP, Apperley JF, Jones L, Batchelor JR, Brookes P, Catovsky D, Galton DAG, Bidwell J, Bradley B, Cleaver S, Hale G, Waldmann H. Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated donors. 1990 Experimental Hematology 18(5) 421-425. CIT 52
  281. Hughes TP, Martiat P, Morgan G, Sawyers C, Witte ON, Goldman JM. Significance of residual leukaemia transcripts after bone marrow transplant for CML (letter) 1990 Lancet 335:50 CIT 18
  282. Hughes TP, Goldman JM. Biological importance of residual leukaemic cells after BMT for CML: can the polymerase chain reaction help? 1990 Bone Marrow Transplantation 5(1)3-6. CIT 23
  283. Kaminski E, Hows J, Brookes P, Mackinnon S, Hughes TP, Ovakian O, Goldman J, Batchelor JR. Alloreactive cytotoxic T-cell frequency analysis and HLA matching for bone marrow transplants from HLA matched unrelated donors. 1989 Transplantation Proceedings 21(1) 2976-2977. CIT 9
  284. Morgan GJ, Janssen JWG, Guo AP, Wiedemann LM, Hughes TP, Gow J, Goldman JM, , Bartram C. Polymerase chain reaction for the detection of residual leukaemia. 1989 Lancet 333(8644) 928-929. CIT 166
  285. Hughes TP, Jones P, Rozenberg MC. Hypergammaglobulinemia and the asnticardiolipin antibody test (letter) 1989 Arthritis and Rheumatism 32:813 CIT 19
  286. Hughes TP, Economou K, Mackinnon S, Vlitos M, Arthur CK, Guo AP, Rassool F, Apperley JF, Hows J, Goldman JM. Slow evolution of chronic myeloid leukaemia relapsing after BMT with T-cell depleted donor marrow. 1989 British Journal of Haematology 73(4) 462-467. CIT 33

Books, Chapters

  1. Hughes TP, and Goldman, JM. Chronic Myeloid Leukemia. 1995 In: Hematology: Basic Principles and Practices. Hoffman, Benz, Shattil, Furie, Cohen (Eds.) NY: Churchill Livingstone, pp. 854-869 CIT 45
  2. Hui CH, Hughes TP. Strategies for the treatment of imatinib-resistant chronic myeloid leukaemia. 2003 Clinical Advances in Hematology and Oncology 1:538-545 CIT 7
  3. Hughes TP. Molecular monitoring in chronic myeloid leukemia in Hematology 2003 American Society of Hematology Education Program Book.
  4. Melo JV, Hughes TP, Apperley JF. Chronic Myeloid Leukemia. ASH Education Program Book 2003 (1) 132-152. CIT 176
  5. Ross DM, Hughes TP. 2004 Cancer treatment with kinase inhibitors: what have we learnt from imatinib? British Journal of Cancer 90(1):12-9 CIT 46
  6. Faderl S, Hochhaus A, Hughes TP 2004. Monitoring of minimal residual disease in CML North American Clinics in Hematology and Oncology 18(3):657-70. CIT 30
  7. Hochhaus A, Hughes TP 2004 Clinical resistance to imatinib: mechanisms and implications. North American Clinics in Hematology and Oncology 18(3)641-56. CIT 112
  8. Ross DM, Hughes TP. 2004 Cancer treatment with kinase inhibitors: what have we learnt from imatinib? Br J Cancer 90(1):12-19 CIT 45
  9. Hughes TP, Branford S. Molecular monitoring of CML. Semin Haematol 40 No: 2 (suppl 2) 62-68 CIT 98
  10. Hughes TP. Comments on the Hammersmith Policy Semin Haematol 40, No 2 (suppl 2) 111-112
  11. Hughes TP. ABL Kinase Inhibitor Therapy for CML: Baseline Assessments and Response Monitoring. ASH Education Program Book. 2006 211-218 CIT 50
  12. Branford S, Hughes TP. Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med. 2006 1125: 93-106 CIT 98
  13. Branford S, Hughes TP. Diagnosis and monitoring of chronic myeloid leukaemia by qualitative and quantitative RT-PCR. Methods Mol Med. 2006 125: 69-92 CIT 63
  14. Hurst N, Hughes TP, Branford S. Monitoring CML: State of the art. In: Cortes J Deininger M eds. Chronic Myelogenous Leukaemia. 2006
  15. Hughes TP, Branford S. Monitoring Disease Response. In: Melo JV, Goldman J Meds. Myeloproliferative disorders. Haematologic Malignancies. Berlin: Springer-Verlag. 2007 143-164
  16. Hughes TP, Branford S. Monitoring disease response to tyrosine kinase inhibitor therapy in CML. 2009 ASH Education Program (1) 477-787 CIT 86
  17. Hughes TP, White D. Which TKI? An embarrassment of riches for chronic myeloid leukemia patients. Hematology American Society of Hematology Education Program. 2013 (1) 168-175 CIT 48
  18. Hughes TP, Ross D, Melo J: Handbook on Management of patients with Chronic Myeloid Leukemia. Springer International Publishing 2014 35-51 CIT 5
  19. Ross DM, Hughes TP. Discontinuation of Therapy and Treatment-Free Remission in CML. Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia. 2016 183-193 Springer Japan. CIT 1
  20. Yeung DT, Hughes TP, Chronic Myeloid Leukemia. In: Hoffbrand AV, Higgs DR, Keeling DM and Mehta AB eds. Postgraduate Haematology 7th Edition. Oxford, UK: John Wiley & Sons. 2016 419-437. CIT 1

Return to Professor Tim Hughes' biography

Get in touch
+61 8 8128 4000
You can't miss us!
North Terrace Adelaide 5000 South Australia
Postal Address
PO BOX 11060 Adelaide 5001 South Australia
Key Partners
SAHMRI is located on the traditional lands of the Kaurna Nation.

The SAHMRI community acknowledges and respects the traditional owners, the family clans who are the Kaurna Nation from the Adelaide Plains region of South Australia. We acknowledge the clans of the Kaurna Nation and the sacred knowledge they hold for their country. We pay our respects to the Kaurna Nation, their ancestors and the descendants of these living family clans today.